Cite
Blaise M, Rocher F, Spittler H, et al. Severe necrotizing myopathy after COVID-19 vaccine with BNT162b2 and regimen with ipilimumab plus nivolumab in a patient with advanced melanoma. J Eur Acad Dermatol Venereol. 2021;doi: 10.1111/jdv.17760.
Blaise, M., Rocher, F., Spittler, H., Sanchez, A., Lanteri, E., Coco, L., Puma, A., Martel, A., Gonfrier, G., Passeron, T., & Montaudié, H. (2021). Severe necrotizing myopathy after COVID-19 vaccine with BNT162b2 and regimen with ipilimumab plus nivolumab in a patient with advanced melanoma. Journal of the European Academy of Dermatology and Venereology : JEADV, . https://doi.org/10.1111/jdv.17760
Blaise, M, et al. "Severe necrotizing myopathy after COVID-19 vaccine with BNT162b2 and regimen with ipilimumab plus nivolumab in a patient with advanced melanoma." Journal of the European Academy of Dermatology and Venereology : JEADV vol. (2021). doi: https://doi.org/10.1111/jdv.17760
Blaise M, Rocher F, Spittler H, Sanchez A, Lanteri E, Coco L, Puma A, Martel A, Gonfrier G, Passeron T, Montaudié H. Severe necrotizing myopathy after COVID-19 vaccine with BNT162b2 and regimen with ipilimumab plus nivolumab in a patient with advanced melanoma. J Eur Acad Dermatol Venereol. 2021 Oct 17; doi: 10.1111/jdv.17760. Epub 2021 Oct 17. PMID: 34661938; PMCID: PMC8661524.
Copy
Download .nbib